TR201903066T4 - E. colı'de enzimatik konjugasyonla rekombinant aşı üretimi. - Google Patents

E. colı'de enzimatik konjugasyonla rekombinant aşı üretimi. Download PDF

Info

Publication number
TR201903066T4
TR201903066T4 TR2019/03066T TR201903066T TR201903066T4 TR 201903066 T4 TR201903066 T4 TR 201903066T4 TR 2019/03066 T TR2019/03066 T TR 2019/03066T TR 201903066 T TR201903066 T TR 201903066T TR 201903066 T4 TR201903066 T4 TR 201903066T4
Authority
TR
Turkey
Prior art keywords
coli
production
recombinant vaccine
enzymatic conjugation
glycoconjugates
Prior art date
Application number
TR2019/03066T
Other languages
English (en)
Turkish (tr)
Inventor
Wacker Michael
Kowarik Michael
Wetter Michael
Faridmoayer Amirreza
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of TR201903066T4 publication Critical patent/TR201903066T4/tr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/005Glycopeptides, glycoproteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
TR2019/03066T 2012-11-07 2013-11-07 E. colı'de enzimatik konjugasyonla rekombinant aşı üretimi. TR201903066T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261723408P 2012-11-07 2012-11-07

Publications (1)

Publication Number Publication Date
TR201903066T4 true TR201903066T4 (tr) 2019-03-21

Family

ID=49552366

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/03066T TR201903066T4 (tr) 2012-11-07 2013-11-07 E. colı'de enzimatik konjugasyonla rekombinant aşı üretimi.

Country Status (16)

Country Link
US (2) US20150273043A1 (enExample)
EP (3) EP3444352B1 (enExample)
JP (2) JP6412875B2 (enExample)
KR (1) KR20150079964A (enExample)
CN (1) CN105008539B (enExample)
AU (2) AU2013343520B2 (enExample)
BR (1) BR112015010283A8 (enExample)
CA (2) CA2889767C (enExample)
EA (1) EA201590705A1 (enExample)
ES (3) ES2713166T3 (enExample)
IL (1) IL238586A0 (enExample)
MX (1) MX366912B (enExample)
SG (1) SG11201503308XA (enExample)
TR (1) TR201903066T4 (enExample)
WO (1) WO2014072405A1 (enExample)
ZA (1) ZA201503097B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010322454B2 (en) * 2009-11-19 2016-05-19 Glaxosmithkline Biologicals S.A. Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells
US11220676B2 (en) * 2013-10-11 2022-01-11 Glaxosmithkline Biological Sa Methods of host cell modification
EA035991B9 (ru) 2014-02-24 2020-10-21 Глаксосмитклайн Байолоджикалс С.А. Новый полисахарид и его применения
SI3131577T1 (sl) * 2014-04-17 2020-08-31 Glaxosmithkline Biologicals S.A. Modificirane gostiljske celice in uporabe le-teh
SG11201700325SA (en) * 2014-08-08 2017-02-27 Glycovaxyn Ag Modified host cells and hybrid oligosaccharides for use in bioconjugate production
AU2016224006B8 (en) * 2015-02-26 2020-03-19 Vaxnewmo Llc Acinetobacter O-oligosaccharyltransferases and uses thereof
GB201518668D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
CN105963691B (zh) * 2016-07-03 2020-05-01 查文娟 一种肺炎链球菌疫苗
CN106929573B (zh) * 2017-02-21 2020-06-09 南开大学 对嗜肺军团菌O12型的wzm和wecA基因特异的核苷酸序列及其应用
GB201712678D0 (en) * 2017-08-07 2017-09-20 Glaxosmithkline Biologicals Sa Process for the manipulation of nucleic acids
WO2019043245A1 (en) * 2017-09-04 2019-03-07 London School Of Hygiene And Tropical Medicine MICROBIAL CELLS EXPRESSING STREPTOCOCCAL SERROTYPES
WO2019090138A2 (en) * 2017-11-04 2019-05-09 Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno Immunogenic conjugates and methods of use thereof
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
WO2019241672A2 (en) 2018-06-16 2019-12-19 Vaxnewmo Llc Glycosylated comp pilin variants, methods of making and uses thereof
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
EP3650044A1 (en) * 2018-11-06 2020-05-13 ETH Zürich Anti-glycan vaccines
US12350342B2 (en) 2018-12-21 2025-07-08 Vaxnewmo Llc O-linked glycosylation recognition motifs
IL286467B1 (en) 2019-03-18 2025-10-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of E. COLI O-antigen polysaccharides, preparations thereof and methods for using them
EP3770269A1 (en) 2019-07-23 2021-01-27 GlaxoSmithKline Biologicals S.A. Quantification of bioconjugate glycosylation
CN112369722B (zh) * 2020-05-08 2023-03-17 湖北中烟工业有限责任公司 加热不燃烧装置和温度控制方法
CN111518738B (zh) * 2020-05-08 2022-02-08 徐州海润生物科技有限公司 重组卡介苗及其制备方法和应用
CA3185719A1 (en) * 2020-06-18 2021-12-23 Glaxosmithkline Biologicals Sa Shigella-tetravalent (shigella4v) bioconjugate
US20230293657A1 (en) 2020-06-25 2023-09-21 Glaxosmithkline Biologicals Sa Vaccine
KR20230043157A (ko) 2020-09-17 2023-03-30 얀센 파마슈티칼즈, 인코포레이티드 다가 백신 조성물 및 이의 용도
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
EP4452308A1 (en) 2021-12-22 2024-10-30 GlaxoSmithKline Biologicals S.A. Vaccine
GB202302579D0 (en) 2023-02-23 2023-04-12 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2025172892A1 (en) 2024-02-16 2025-08-21 Glaxosmithkline Biologicals Sa Modified proteins and methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2638595A (en) * 1994-05-16 1995-12-05 Uab Research Foundation, The (streptococcus pneumoniae) capsular polysaccharide genes and flanking regions
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US7541043B2 (en) 2002-01-16 2009-06-02 The United States Of America As Represented By The Department Of Health And Human Services Vaccine for protection against Shigella sonnei disease
CA2477794C (en) 2002-03-07 2013-08-20 Eidgenoessische Technische Hochschule Zuerich System and method for the production of recombinant glycosylated proteins in a prokaryotic host
JP5356807B2 (ja) 2005-05-11 2013-12-04 アイトヘネーシシェ テフニーシェ ホフシューレ チューリッヒ 原核細胞由来の組み換えn−グリコシル化タンパク質
HRP20181259T1 (hr) 2008-02-20 2018-10-05 Glaxosmithkline Biologicals S.A. Biokonjugati načinjeni iz rekombinantnih n-glikoziliranih proteina iz prokariotskih stanica
CA2756170C (en) * 2009-03-23 2019-04-02 The Brigham And Women's Hospital, Inc. Glycoconjugate vaccines
KR20120085240A (ko) 2009-07-17 2012-07-31 오션 하베스트 테크놀로지 (캐나다) 아이엔씨. 어류 사료에서 합성 첨가제를 대체하는 천연 및 지속 가능 해조류 배합
ES2844596T3 (es) 2010-05-06 2021-07-22 Glaxosmithkline Biologicals Sa Vacunas de bioconjugados de bacterias grampositivas capsulares
TR201904022T4 (tr) * 2012-10-12 2019-04-22 Glaxosmithkline Biologicals Sa Konakçı hücre modifikasyon yöntemleri.

Also Published As

Publication number Publication date
EP3444352A3 (en) 2019-03-27
WO2014072405A1 (en) 2014-05-15
EA201590705A1 (ru) 2016-05-31
ES2882282T3 (es) 2021-12-01
BR112015010283A2 (pt) 2017-07-11
EP2917351B1 (en) 2018-12-19
EP2917351A1 (en) 2015-09-16
MX366912B (es) 2019-07-30
ES2713166T3 (es) 2019-05-20
JP2015533511A (ja) 2015-11-26
CA2889767C (en) 2021-09-21
BR112015010283A8 (pt) 2021-07-06
EP3508579A1 (en) 2019-07-10
ES2848774T3 (es) 2021-08-11
EP3444352B1 (en) 2020-12-16
EP3444352A2 (en) 2019-02-20
JP6833785B2 (ja) 2021-02-24
CN105008539A (zh) 2015-10-28
SG11201503308XA (en) 2015-05-28
CA3125293A1 (en) 2014-05-15
AU2017279688B2 (en) 2019-11-14
US10973901B2 (en) 2021-04-13
AU2017279688A1 (en) 2018-01-18
AU2013343520B2 (en) 2017-09-28
US20150273043A1 (en) 2015-10-01
US20190076517A1 (en) 2019-03-14
IL238586A0 (en) 2015-06-30
JP2019030309A (ja) 2019-02-28
ZA201503097B (en) 2018-11-28
MX2015005797A (es) 2016-03-09
EP3508579B1 (en) 2021-06-30
CN105008539B (zh) 2020-04-17
CA2889767A1 (en) 2014-05-15
AU2013343520A1 (en) 2015-06-04
KR20150079964A (ko) 2015-07-08
JP6412875B2 (ja) 2018-10-24

Similar Documents

Publication Publication Date Title
TR201903066T4 (tr) E. colı'de enzimatik konjugasyonla rekombinant aşı üretimi.
EA201491441A1 (ru) Композиции конъюгата xten и способы их получения
ZA201601534B (en) Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
EP4253395A3 (en) Processes for the preparation of carbohydrate conjugated rna agents
PH12015502493B1 (en) Compositions and methods for modulating hbv and ttr expression
MX352324B (es) Vacunas multivalentes de nanovehiculos sinteticos.
PH12014501229A1 (en) Antibody-drug conjugates and related compounds, compositions, and methods
MX2023010178A (es) Conjugados de anticuerpo farmaco anti-cd70.
MX344009B (es) Conjugados de amatoxinas con enlaces mejorados.
SG10201900948PA (en) Modified nucleotide linkers
EA201200091A1 (ru) Штаммы talaromyces и ферментные композиции
PH12013500386A1 (en) Pesticidal compositions
MX2016007063A (es) Peptidos terapeuticos.
MX2016008448A (es) Conjugados de var2csa-farmaco.
EA201290876A1 (ru) Композиции индуцированных дендритных клеток и их использование
MX2013004353A (es) Produccion recombinante de n-propanol e isopropanol.
IN2012DN02210A (enExample)
FI20115328A0 (fi) Uusia kutinaaseja, niiden tuottaminen ja käytöt
GB201017519D0 (en) Vaccines
BR112016007671A2 (pt) adição em estágio tardio de modificador de reologia
GB201110777D0 (en) Methods and uses
MX2013003859A (es) Polimorfos de picropodofilina b o c para su uso en la terapia del cancer.
MX2024002130A (es) Metodos y composiciones para mejorar la expresion de proteinas recombinantes.
MX2014010958A (es) Composicion de celulas inmunoestimuladora activada y sus usos.
RU2010119250A (ru) Штамм bifidobacterium adolescentis рвв-1, используемый для получения продукции